Core Insights - Arcutis Biotherapeutics announced positive results from the INTEGUMENT-INFANT Phase 2 trial for ZORYVE® (roflumilast) cream 0.05%, showing its effectiveness in treating atopic dermatitis in infants aged 3 months to less than 24 months [1][5][6] Group 1: Clinical Trial Results - ZORYVE cream 0.05% significantly reduced signs and symptoms of atopic dermatitis in infants, with caregivers reporting rapid relief of itch in as little as 10 minutes [2][5] - In the trial, 34.4% of participants achieved Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) success at Week 4, and 49% achieved a vIGA-AD score of Clear or Almost Clear [3][4] - The study demonstrated a high safety profile, with only one participant discontinuing due to an adverse event and no serious adverse events reported [2][6] Group 2: Safety and Tolerability - The most frequently reported adverse events included diarrhea, nasopharyngitis, upper respiratory tract infection, and vomiting, with a high local tolerability rate of ≥97.9% experiencing no application site irritation [2][6] - The safety findings were consistent with previous pediatric studies, reinforcing the well-tolerated nature of ZORYVE cream [5][6] Group 3: Future Developments - Arcutis plans to submit a supplemental New Drug Application for ZORYVE cream 0.05% for infants in Q2 2026, expanding its evidence base for this vulnerable population [6] - Additional studies supporting the ZORYVE portfolio were presented, indicating ongoing commitment to developing effective treatments for various dermatological conditions [7][8]

Core Insights - Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3% for treating plaque psoriasis in patients aged 12 and older, marking a significant advancement in immuno-dermatology [1][5] - ZORYVE foam is a once-daily, steroid-free treatment that is now widely available, addressing the needs of nearly 9 million people in the U.S. living with plaque psoriasis, particularly those with scalp involvement [2][5] Product Details - ZORYVE foam demonstrated significant improvements in clinical trials, achieving Scalp-Investigator Global Assessment (S-IGA) Success in 66.4% of patients compared to 27.8% for the vehicle foam at Week 8 [8] - The foam also provided rapid itch relief, with 65.3% of patients experiencing a clinically significant reduction in scalp itch compared to 30.3% for the vehicle [10] - ZORYVE is indicated for both plaque psoriasis and seborrheic dermatitis, with a focus on hard-to-treat areas such as the scalp and body [14][15] Clinical Trial Results - The approval was supported by positive results from Phase 2 and pivotal Phase 3 trials, enrolling 736 adults and adolescents with mild to severe plaque psoriasis [7] - In the ARRECTOR study, 45.5% of individuals treated with ZORYVE foam achieved Body-IGA Success compared to 20.1% for the vehicle foam at Week 8 [8] - The treatment was well tolerated, with low incidence of adverse events, primarily mild to moderate in severity [12] Market Context - The approval of ZORYVE foam is the fifth for the product in less than three years, highlighting Arcutis' commitment to addressing urgent needs in dermatology [3][5] - The company aims to provide predictable access to ZORYVE through programs that assist patients with adherence and reduce out-of-pocket costs [4][21] Future Engagement - Arcutis will host a virtual Key Opinion Leader Event on June 2, 2025, to discuss the treatment landscape for plaque psoriasis, featuring insights from a leading expert [4][5]